Pattern of relapse and progression after autologous SCT as upfront treatment for multiple myeloma

Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study

(2012) L. Rosinol et al.   BLOOD

Patterns of relapse and progression in multiple myeloma patients after auto-SCT: implications for patients’ monitoring after transplantation

(2012) D Zamarin et al.   BONE MARROW TRANSPLANTATION

Redefining myeloma

(2012) S. Vincent Rajkumar et al.   Nature Reviews Clinical Oncology

Lenalidomide in Myeloma — A High-Maintenance Friend

(2012) Ashraf Z. Badros   NEW ENGLAND JOURNAL OF MEDICINE

Long-term prognostic significance of response in multiple myeloma after stem cell transplantation

(2011) J. Martinez-Lopez et al.   BLOOD

Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1

(2011) S. V. Rajkumar et al.   BLOOD

Soft-Tissue Plasmacytomas in Multiple Myeloma: Incidence, Mechanisms of Extramedullary Spread, and Treatment Approach

(2011) Joan Bladé et al.   JOURNAL OF CLINICAL ONCOLOGY

Hematopoietic stem cell transplantation for multiple myeloma beyond 2010

(2010) J. Blade et al.   BLOOD

Relapse of multiple myeloma in extramedullary sites after autologous bone marrow transplantation

(2010) C. Sanfructuoso et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients

(2009) M. Varettoni et al.   ANNALS OF ONCOLOGY

The impact of extramedullary disease at presentation on the outcome of myeloma

(2009) Ping Wu et al.   LEUKEMIA & LYMPHOMA

Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma

(2008) R A Kyle et al.   LEUKEMIA